|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||82.30 - 83.26|
|52 Week Range||66.72 - 92.97|
|PE Ratio (TTM)||11.51|
|Dividend & Yield||3.30 (3.49%)|
|1y Target Est||N/A|
In 2Q17, Sanofi Genzyme (SNY) reported revenue growth of 13.5% to 1.7 billion euros. Considering a constant structure and constant exchange rates, the growth was 14.4%. Sanofi Genzyme, which includes product ...
At constant exchange rates, Sanofi (SNY) reported revenue growth of ~5.5% between 2Q16 and 2Q17, with revenue rising to 8.7 billion euros from 8.1 billion euros. The above chart shows Sanofi’s…
Spectrum Pharmaceuticals, Inc. (SPPI) initiated the registrational phase III study of qapzola in patients with non-muscle invasive bladder cancer (NMIBC) as per the FDA's requirement.